Intracoastal Capital discloses 8.1% Processa (PCSA) ownership stake
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Processa Pharmaceuticals received an amended Schedule 13G showing that investors Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC collectively reported beneficial ownership of 200,000 shares of common stock issuable upon exercise of a warrant held by Intracoastal.
As of December 31, 2025, these warrant shares represented approximately 8.1% of Processa’s common stock, based on 2,265,768 shares outstanding as of December 12, 2025 plus the 200,000 warrant shares. The filers report shared voting and dispositive power over all 200,000 shares and certify the holding is not for the purpose of changing or influencing control.
Positive
- None.
Negative
- None.
FAQ
What stake in Processa Pharmaceuticals (PCSA) is reported in this Schedule 13G/A?
The filing reports beneficial ownership of 200,000 shares of common stock. These shares are issuable upon exercise of a warrant held by Intracoastal Capital LLC and represent approximately 8.1% of Processa’s common stock based on the outstanding share count cited.
Who are the reporting persons in the Processa (PCSA) Schedule 13G/A filing?
The reporting persons are Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC. Kopin and Asher are U.S. individuals, while Intracoastal is a Delaware limited liability company, and together they are treated as a group of reporting holders.
How was the 8.1% ownership in Processa (PCSA) calculated in the filing?
The 8.1% figure is based on 2,265,768 Processa shares outstanding plus 200,000 warrant shares. The calculation uses the issuer’s reported outstanding shares as of December 12, 2025 and adds the common stock issuable upon exercise of the Intracoastal warrant.
Is the Intracoastal Capital LLC position in Processa (PCSA) a passive investment?
The filers certify the securities are not held to change or influence control. They state the shares were not acquired and are not held for control-related purposes, consistent with a passive investment stance under the Schedule 13G framework.
What triggered this amended Schedule 13G for Processa Pharmaceuticals (PCSA)?
The statement reflects ownership as of December 31, 2025. At that date, the reporting persons may be deemed to beneficially own 200,000 Processa shares via a warrant, crossing the 5% threshold that requires Schedule 13G reporting and subsequent amendments.